Bbva Compass Bancshares Inc. reduced its stake in shares of Boston Scientific Corp. (NYSE:BSX) by 35.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 112,643 shares of the company’s stock after selling 60,871 shares during the period. Bbva Compass Bancshares Inc.’s holdings in Boston Scientific Corp. were worth $2,681,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. increased its position in Boston Scientific Corp. by 3.9% in the third quarter. Oppenheimer & Co. Inc. now owns 11,265 shares of the company’s stock valued at $269,000 after buying an additional 423 shares in the last quarter. Robeco Institutional Asset Management B.V. increased its position in Boston Scientific Corp. by 3.9% in the third quarter. Robeco Institutional Asset Management B.V. now owns 107,143 shares of the company’s stock valued at $2,550,000 after buying an additional 4,065 shares in the last quarter. Prudential Financial Inc. increased its position in Boston Scientific Corp. by 123.1% in the third quarter. Prudential Financial Inc. now owns 4,380,019 shares of the company’s stock valued at $104,245,000 after buying an additional 2,417,148 shares in the last quarter. Ngam Advisors L.P. increased its position in Boston Scientific Corp. by 3.2% in the third quarter. Ngam Advisors L.P. now owns 59,353 shares of the company’s stock valued at $1,413,000 after buying an additional 1,839 shares in the last quarter. Finally, Sentry Investment Management LLC increased its position in Boston Scientific Corp. by 4.1% in the third quarter. Sentry Investment Management LLC now owns 105,215 shares of the company’s stock valued at $2,504,000 after buying an additional 4,189 shares in the last quarter. Hedge funds and other institutional investors own 89.96% of the company’s stock.

Institutional Ownership by Quarter for Boston Scientific Corp. (NYSE:BSX)

Boston Scientific Corp. (NYSE:BSX) traded down 1.49% during mid-day trading on Wednesday, reaching $20.46. 12,496,799 shares of the company’s stock were exchanged. Boston Scientific Corp. has a one year low of $15.67 and a one year high of $24.79. The stock has a 50-day moving average of $21.92 and a 200-day moving average of $23.07. The stock has a market cap of $27.86 billion, a price-to-earnings ratio of 386.04 and a beta of 1.15.

Boston Scientific Corp. (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 26th. The company reported $0.27 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.27. The firm earned $2.11 billion during the quarter, compared to the consensus estimate of $2.07 billion. Boston Scientific Corp. had a return on equity of 23.25% and a net margin of 0.99%. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter last year, the company posted $0.24 EPS. On average, equities research analysts anticipate that Boston Scientific Corp. will post $1.10 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The legal version of this report can be accessed at http://www.dailypolitical.com/2016/11/30/bbva-compass-bancshares-inc-lowers-position-in-boston-scientific-corp-bsx.html.

Several research firms have commented on BSX. Zacks Investment Research downgraded shares of Boston Scientific Corp. from a “buy” rating to a “hold” rating in a report on Monday, October 31st. TheStreet raised shares of Boston Scientific Corp. from a “hold” rating to a “buy” rating in a research report on Wednesday, October 26th. Royal Bank Of Canada reissued an “outperform” rating and issued a $28.00 target price on shares of Boston Scientific Corp. in a research report on Friday, October 14th. Citigroup Inc. boosted their target price on shares of Boston Scientific Corp. from $28.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, October 6th. Finally, Argus raised shares of Boston Scientific Corp. from a “hold” rating to a “buy” rating and boosted their target price for the company from $23.82 to $33.00 in a research report on Thursday, September 1st. They noted that the move was a valuation call. Five equities research analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $25.70.

Boston Scientific Corp. Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.

5 Day Chart for NYSE:BSX

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corp. (NYSE:BSX).

Receive News & Ratings for Boston Scientific Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corp. and related companies with MarketBeat.com's FREE daily email newsletter.